- Conditions
- Adult Brain Tumor, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Melanocytic Lesion, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma, Adult Pineocytoma, Recurrent Adult Brain Tumor
- Interventions
- proton beam radiation therapy, quality-of-life assessment, questionnaire administration
- Radiation · Procedure · Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 57
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
- Interventions
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain Tumor, Medulloblastoma, Pineoblastoma
- Interventions
- proton beam radiation
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
- Interventions
- Questionnaire
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Metabolic Syndrome, Sarcoma
- Interventions
- metabolic assessment, questionnaire administration
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Interventions
- Melphalan
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
- Interventions
- Placebo Administration, Questionnaire Administration, Wound Dressing Material
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years to 17 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma, Embryonal Rhabdomyosarcoma of Cervix, Goiter, Sarcoma, Pineoblastoma, Pituitary Tumors, Wilms Tumor
- Interventions
- Not listed
- Lead sponsor
- Ashley Hill
- Other
- Eligibility
- 1 Day to 95 Years
- Enrollment
- 1,247 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Malignant Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineocytoma, Malignant Neoplasm, Meningeal Melanocytoma, Radiation Toxicity, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
- Interventions
- bevacizumab, placebo, magnetic resonance imaging, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, temozolomide, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- carboxyamidotriazole, paclitaxel
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
- Conditions
- Brain Tumors, Metastatic Disease
- Interventions
- donepezil hydrochloride, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 16
- States / cities
- Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Supratentorial Ependymoma, Meningeal Melanocytoma, Newly Diagnosed Childhood Ependymoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Pleomorphic Xanthoastrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Medulloblastoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilocytic Astrocytoma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Pineoblastoma, Untreated Childhood Pleomorphic Xanthoastrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
- Interventions
- gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis
- Radiation · Procedure · Other
- Lead sponsor
- Sue O'Dorisio
- Other
- Eligibility
- 6 Months to 29 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Brain and Central Nervous System Tumors, Radiation Toxicity
- Interventions
- EGb761, donepezil hydrochloride, cognitive assessment
- Dietary Supplement · Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more
- Conditions
- Cancer
- Interventions
- Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
- Conditions
- Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
- Interventions
- Nivolumab, EKG, MRI Brain and/or spine, Body CT Scan, MDASI-BT, MDASI-SP
- Drug · Diagnostic Test · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Houston, Texas
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide Phosphate, Isotretinoin, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Thiotepa, Vincristine Sulfate, Vorinostat
- Radiation · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Months to 47 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
- Interventions
- HER2-specific chimeric antigen receptor (CAR) T cell
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2039
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
- Interventions
- radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study
- Radiation · Drug · Other
- Lead sponsor
- Lawrence Recht
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
- Interventions
- Adavosertib, Irinotecan Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
- Conditions
- Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS, Fibrillary Astrocytoma, Low-Grade Astrocytoma, Nos, Pilocytic Astrocytoma, Choroid Plexus Carcinoma, CNS Primary Tumor, Nos, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, Ependymoma, NOS, Anaplastic Oligodendroglioma, Oligodendroglioma, Nos, CNS Germ Cell Tumor, Pineoblastoma, Diffuse Leptomeningeal Glioneuronal Tumor
- Interventions
- Not listed
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 40 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more